TORONTO and HAIFA, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, is pleased to announce its financial results for the second quarter ended June 30, 2026 (“Q2”), and to provide a corporate update